Hormone-sensitive BC (ER+ or PR+) represents about the 75% of newly diagnosed BC and up to 70% of cases of metastatic disease are estrogen receptor positive (ER+) tumors [1,9]. Here, ESR1 is linked to metastatic neoplasm.